196 related articles for article (PubMed ID: 31898097)
41. Lobular carcinoma in situ and invasive cancer: the contralateral breast controversy.
Carolin KA; Tekyi-Mensah S; Pass HA
Breast J; 2002; 8(5):263-8. PubMed ID: 12199752
[TBL] [Abstract][Full Text] [Related]
42. Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma
Trivedi MS; Coe AM; Vanegas A; Kukafka R; Crew KD
Cancer Prev Res (Phila); 2017 Aug; 10(8):434-441. PubMed ID: 28611039
[TBL] [Abstract][Full Text] [Related]
43. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy.
Jolly S; Kestin LL; Goldstein NS; Vicini FA
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):365-71. PubMed ID: 16965988
[TBL] [Abstract][Full Text] [Related]
44. Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population.
Phipps AI; Li CI; Kerlikowske K; Barlow WE; Buist DS
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1643-54. PubMed ID: 20501751
[TBL] [Abstract][Full Text] [Related]
45. Lobular carcinoma in situ and invasive lobular cancer of the breast.
Cocquyt V; Van Belle S
Curr Opin Obstet Gynecol; 2005 Feb; 17(1):55-60. PubMed ID: 15711412
[TBL] [Abstract][Full Text] [Related]
46. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer.
Li CI; Daling JR; Malone KE; Bernstein L; Marchbanks PA; Liff JM; Strom BL; Simon MS; Press MF; McDonald JA; Ursin G; Burkman RT; Deapen D; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):946-54. PubMed ID: 16702375
[TBL] [Abstract][Full Text] [Related]
47. [Lobular carcinoma in situ of the breast].
Llanos Muñoz M; Alonso Muñoz MC; Ojeda González B
Med Clin (Barc); 1994 Oct; 103(14):553-6. PubMed ID: 7799670
[No Abstract] [Full Text] [Related]
48. The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy.
Abner AL; Connolly JL; Recht A; Bornstein B; Nixon A; Hetelekidis S; Silver B; Harris JR; Schnitt SJ
Cancer; 2000 Mar; 88(5):1072-7. PubMed ID: 10699897
[TBL] [Abstract][Full Text] [Related]
49. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma?
Bagaria SP; Shamonki J; Kinnaird M; Ray PS; Giuliano AE
Ann Surg Oncol; 2011 Jul; 18(7):1845-51. PubMed ID: 21287281
[TBL] [Abstract][Full Text] [Related]
50. Lobular carcinoma in situ as a component of breast cancer: the long-term outcome in patients treated with breast-conservation therapy.
Moran M; Haffty BG
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):353-8. PubMed ID: 9457821
[TBL] [Abstract][Full Text] [Related]
51. Invasive breast cancer following ductal and lobular carcinoma in situ of the breast.
Levi F; Randimbison L; Te VC; La Vecchia C
Int J Cancer; 2005 Sep; 116(5):820-3. PubMed ID: 15838829
[TBL] [Abstract][Full Text] [Related]
52. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ.
Fisher ER; Land SR; Fisher B; Mamounas E; Gilarski L; Wolmark N
Cancer; 2004 Jan; 100(2):238-44. PubMed ID: 14716756
[TBL] [Abstract][Full Text] [Related]
53. Breast cancer risk factors in younger and older women.
Chun J; Pocock B; Joseph KA; El-Tamer M; Klein L; Schnabel F
Ann Surg Oncol; 2009 Jan; 16(1):96-9. PubMed ID: 18979140
[TBL] [Abstract][Full Text] [Related]
54. Interpretation of the risk associated with the unexpected finding of lobular carcinoma in situ.
Zurrida S; Bartoli C; Galimberti V; Raselli R; Barletta L
Ann Surg Oncol; 1996 Jan; 3(1):57-61. PubMed ID: 8770303
[TBL] [Abstract][Full Text] [Related]
55. Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy.
Shin SJ; Rosen PP
Arch Pathol Lab Med; 2002 Jun; 126(6):697-701. PubMed ID: 12033958
[TBL] [Abstract][Full Text] [Related]
56. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review.
De Brot M; Koslow Mautner S; Muhsen S; Andrade VP; Mamtani A; Murray M; Giri D; Sakr RA; Brogi E; King TA
Breast Cancer Res Treat; 2017 Sep; 165(2):411-420. PubMed ID: 28612228
[TBL] [Abstract][Full Text] [Related]
57. Clinical importance of histologic grading of lobular carcinoma in situ in breast core needle biopsy specimens: current issues and controversies.
Gao F; Carter G; Tseng G; Chivukula M
Am J Clin Pathol; 2010 May; 133(5):767-71. PubMed ID: 20395524
[TBL] [Abstract][Full Text] [Related]
58. The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry.
Claus EB; Stowe M; Carter D; Holford T
Breast; 2003 Dec; 12(6):451-6. PubMed ID: 14659121
[TBL] [Abstract][Full Text] [Related]
59. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
Renshaw AA; Gould EW
Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
[TBL] [Abstract][Full Text] [Related]
60. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast.
Buerger H; Simon R; Schäfer KL; Diallo R; Littmann R; Poremba C; van Diest PJ; Dockhorn-Dworniczak B; Böcker W
Mol Pathol; 2000 Jun; 53(3):118-21. PubMed ID: 10897329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
